Dr. Gillentine is a Director in the Biotechnology/Chemical Group focusing on the pharmaceutical industry. Because Dr. Gillentine is intimately familiar with the Hatch-Waxman Act, and understands patent litigation strategy in the context of the Abbreviated New Drug Application process and Patent Office Litigation, Dr. Gillentine is sought by both innovator and generic pharmaceutical companies for assistance with intellectual property issues related to their pharmaceutical products.
Dr. Gillentine is experienced in working with clients to implement lifecycle management strategies, including those for personalized medicine patent portfolios. Her practice encompasses both domestic and foreign patent prosecution, including patent drafting and patent prosecution. She has drafted and prosecuted patents related to various pharmaceutical issues. For example, Dr. Gillentine has prosecuted patents related to small molecules, polymorphs, chemical synthesis, pharmaceutical formulations, methods of treatment, drug delivery devices, animal models, vaccines, polymers, genes, and gene expression systems, proteins, and antibodies.
Articles in the National Law Review database by Marsha Rose Gillentine, Ph.D.